{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:07:36Z","timestamp":1789110456164,"version":"build-2803163510"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218780","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:43:07Z","timestamp":1786491787000},"page":"218780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["IL-15 superagonists for reprogramming the immunosuppressive microenvironment in gastrointestinal adenocarcinomas"],"prefix":"10.1016","volume":"659","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-383X","authenticated-orcid":false,"given":"Neeraj","family":"Choudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-8443","authenticated-orcid":false,"given":"Md","family":"Faiyazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-4675","authenticated-orcid":false,"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-5969","authenticated-orcid":false,"given":"Thomas J.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218780_bib1","first-page":"167","article-title":"Immunotherapy in gastrointestinal cancers: current insights","volume":"17","author":"Jiang","year":"2025","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218780_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","article-title":"Deep insight into cytokine storm: from pathogenesis to treatment","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib4","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.4110\/in.2025.25.e17","article-title":"Cytokines in focus: IL-2 and IL-15 in NK adoptive cell cancer immunotherapy","volume":"25","author":"Marr","year":"2025","journal-title":"Immune Netw."},{"key":"10.1016\/j.canlet.2026.218780_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040837","article-title":"Heterodimeric IL-15 in cancer immunotherapy","volume":"13","author":"Bergamaschi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218780_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.190831","article-title":"Impact of the IL-15 superagonist N-803 on lymphatic reservoirs of HIV","volume":"10","author":"Rhein","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218780_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtho.2022.11.008","article-title":"An Interleukin-15 superagonist enables antitumor efficacy of natural killer cells against all molecular variants of SCLC","volume":"18","author":"Fousek","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cell.2026.03.025","article-title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","volume":"189","author":"Marine","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116463","article-title":"Metabolic regulation of immunity in the tumor microenvironment","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218780_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumor response to PD-L1 blockade by contributing to exclusion of T-cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12982","article-title":"Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment","volume":"302","author":"Desbois","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218780_bib20","first-page":"20212","volume":"110","author":"Feig","year":"2013"},{"key":"10.1016\/j.canlet.2026.218780_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081952","article-title":"Stromal cell-derived factor 1\u03b1 (SDF-1\u03b1) in invasive breast cancer: associations with vasculo-angiogenic factors and prognostic significance","volume":"13","author":"Zarychta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.ccell.2022.10.006","article-title":"Retraction notice to: downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53\/MDM2 autoregulatory loop in multiple myeloma development","volume":"40","author":"Pichiorri","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents antitumor immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41467-019-09370-z","article-title":"Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma","volume":"10","author":"Kerdidani","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib27","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T-cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fimmu.2020.00508","article-title":"CD73's potential as an immunotherapy target in gastrointestinal cancers","volume":"11","author":"Harvey","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccell.2022.01.003","article-title":"Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer","volume":"40","author":"Alam","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s42255-022-00730-6","article-title":"Extracellular acidosis restricts one-carbon metabolism and preserves T-cell stemness","volume":"5","author":"Cheng","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.canlet.2026.218780_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumor response to PD-L1 blockade by contributing to exclusion of T-cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib37","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13279-y","article-title":"Temperature dependence of spherical electron transfer in a nanosized [Fe14] complex","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071788","article-title":"Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data","volume":"12","author":"Wei","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib41","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-024-49282-1","article-title":"Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumor development","volume":"15","author":"Varveri","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib42","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200111","article-title":"Mechanisms of immunesuppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine","volume":"10","author":"Yaseen","year":"2020","journal-title":"Open Biol."},{"key":"10.1016\/j.canlet.2026.218780_bib43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41419-024-06598-6","article-title":"Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer","volume":"15","author":"Xiao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218780_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218780_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000664","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort","volume":"8","author":"Cho","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib46","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/s41467-026-68612-z","article-title":"A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region","volume":"17","author":"Gao","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02572-2","article-title":"Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance","volume":"25","author":"Lu","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117045","article-title":"CAFs and T-cells interplay: the emergence of a new arena in cancer combat","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.apsb.2025.10.002","article-title":"The progress and perspective of nanomedicine in modulating the tumor immune microenvironment","volume":"16","author":"Lin","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218780_bib51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218527","article-title":"Neutrophil polarization landscapes in HCC: from immunosuppressive niches to antitumor immunity resuscitation","volume":"651","author":"Sun","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218780_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218780_bib121","article-title":"The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy","volume":"13","author":"Wang","year":"2026","journal-title":"Milit. Med. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib74","doi-asserted-by":"crossref","first-page":"eabo2750","DOI":"10.1126\/scitranslmed.abo2750","article-title":"Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement","volume":"15","author":"Woodworth","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib160","article-title":"Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration","volume":"35","author":"Li","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.canlet.2026.218780_bib161","article-title":"IL-15 superagonist SHR-1501 enhances immune responses in lung cancer by modulating tumor microenvironment","volume":"19","author":"Zhang","year":"2025","journal-title":"Clin. Res. J"},{"key":"10.1016\/j.canlet.2026.218780_bib53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","article-title":"Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent","volume":"38","author":"Guo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218780_bib55","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.canlet.2026.218780_bib56","doi-asserted-by":"crossref","first-page":"23869","DOI":"10.1074\/jbc.M116.733600","article-title":"A novel fusion of ALT-803 (Interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses","volume":"291","author":"Liu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218780_bib57","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1158\/1078-0432.CCR-25-1231","article-title":"FDA Approval summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ","volume":"31","author":"Heiss","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000632","article-title":"IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment","volume":"8","author":"Desbois","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144365","article-title":"NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells","volume":"131","author":"Robinson","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218780_bib61","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1038\/s41598-018-25987-4","article-title":"Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy","volume":"8","author":"Hu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218780_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.omto.2022.02.009","article-title":"A novel fusion protein scaffold 18\/12\/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells","volume":"24","author":"Cubitt","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2026.218780_bib63","article-title":"Nanrilkefusp alfa (SOT101), an IL-15 receptor \u03b2\u03b3 superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers","volume":"6","author":"Champiat","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000632","article-title":"IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment","volume":"8","author":"Desbois","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib65","article-title":"Interleukin 15 in cell-based cancer immunotherapy","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218780_bib66","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1038\/s41598-021-85960-6","article-title":"Metabolic changes of Interleukin-12\/15\/18-stimulated human NK cells","volume":"11","author":"Terr\u00e9n","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218780_bib68","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.2100066","article-title":"Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers","volume":"208","author":"Rubinstein","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000664","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort","volume":"8","author":"Cho","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib70","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1182\/blood-2025-5880","article-title":"IL-2 mutein-mediated improvement of CAR T function in Relapsed\/Refractory diffuse B cell lymphoma","volume":"146","author":"Pavy","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218780_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114584","article-title":"Antifibrotic effects of IL-12-treated natural killer cells on collagen type I regulation in lung fibroblasts","volume":"449","author":"Okuno","year":"2025","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218780_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-024-02404-7","article-title":"From bench to bedside: the past, present and future of IL-21 immunotherapy","volume":"41","author":"Kim","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218780_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118380","article-title":"Harnessing the potential of CAR-NK cell therapy in gastrointestinal cancers: from bench to bedside","volume":"190","author":"Ghorbani Vanan","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib77","article-title":"Advances in IL\u201315\u2013Based cancer immunotherapy and divergent immunological effects of IL\u20132 and IL\u201315 signaling via the shared IL\u20132R\u03b2\u03b3 receptor","volume":"17","author":"Gao","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib78","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","article-title":"Phase I trial of N-803, an IL-15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma","volume":"27","author":"Foltz","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-023-03183-3","article-title":"Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review","volume":"24","author":"Noori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218780_bib80","article-title":"Self-assembled nanoplatforms for cancer immunotherapy: principles, progress and perspectives","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218780_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174310","article-title":"Co-Expression of an IL-15 superagonist facilitates self-enrichment of GD(2)-Targeted CAR-NK cells and mediates PotenT-cell killing in the absence of IL-2","volume":"15","author":"Bodden","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib82","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1016\/j.ymthe.2024.10.021","article-title":"A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib83","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL-15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-Cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib84","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425247.2020.1764933","article-title":"Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.canlet.2026.218780_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s43556-026-00403-w","article-title":"TGF-\u03b2 in tumor development and progression: mechanisms and therapeutics","volume":"7","author":"Liu","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.canlet.2026.218780_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106914","article-title":"Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting","volume":"196","author":"Cerella","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbe.2025.100006","article-title":"Therapeutic applications of immunomodulatory nanomaterials in bladder cancer","volume":"18","author":"Li","year":"2026","journal-title":"Nano Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218780_bib88","unstructured":"E. Rettinger, D. Heckl, M. Hutter, E. Salzmann-Manrique, M. Luedtke, S. Huenecke, M. Bremm, C. Cappel, G. Bug, J. Greil, R. Meisel, E.M. Wagner-Drouet, H. Serve, T. G\u00fcng\u00f6r, J.-H. Klusmann, T. Klingebiel, P. Bader, H. Bonig, First-in-Human study of IL-15\u2013Activated cytokine-induced killer cells after allogeneic HCT shows durable remission and serotherapy-associated immune reconstitution in leukemia, J. Clin. Oncol., 0 JCO-25-01966."},{"key":"10.1016\/j.canlet.2026.218780_bib89","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL-15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-Cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib90","article-title":"The broad spectrum of cancer and immunotherapy: achievements and limitations","volume":"16","author":"Aman","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib91","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-020-02749-8","article-title":"IL-15 superagonist N-803 improves IFN\u03b3 production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells","volume":"70","author":"Van der Meer","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218780_bib92","doi-asserted-by":"crossref","first-page":"16130","DOI":"10.18632\/oncotarget.7470","article-title":"IL-15 superagonist\/IL-15R\u03b1Sushi-Fc fusion complex (IL-15SA\/IL-15R\u03b1Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T-cells, and mediates potent antitumor activity against murine breast and colon carcinomas","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218780_bib93","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.7150\/thno.42998","article-title":"Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218780_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102978","article-title":"Immunocytokines in cancer treatment: a systematic review","volume":"139","author":"Agliardi","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218780_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117177","article-title":"The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds","volume":"178","author":"Bhol","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib109","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8+ T-cells infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218780_bib110","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/s41467-023-39035-x","article-title":"Nanovesicles loaded with a TGF-\u03b2 receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib111","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.7150\/thno.24157","article-title":"Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system","volume":"8","author":"Liu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218780_bib112","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1021\/acs.molpharmaceut.0c00451","article-title":"Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation","volume":"17","author":"Lei","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2026.218780_bib113","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s12951-025-03613-6","article-title":"Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook","volume":"23","author":"Mohammadzadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2026.218780_bib114","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218780_bib115","article-title":"Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches","volume":"16","author":"Dai","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118601","article-title":"Fighting cancer smarter: using hydrogel delivery systems to target chemokines","volume":"192","author":"Khorramdelazad","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091908","article-title":"Injectable Hydrogel-based combination cancer immunotherapy for overcoming localized therapeutic efficacy","volume":"14","author":"Kim","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2026.218780_bib118","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 delivery strategies and advances in tumor immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218780_bib119","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218780_bib98","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib96","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218780_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013533","article-title":"TGF-\u03b2RII\/IL-15 immunotherapeutic complex targets exhausted CD8(+) T-cell subsets in lymph nodes and tumors","volume":"13","author":"George","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib99","article-title":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","volume":"1881","author":"Wang","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218780_bib100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/15353702221089910","article-title":"Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1\/TGF\u03b2RII agent: current status","volume":"247","author":"Gameiro","year":"2022","journal-title":"Exp. Biol. Med. (Maywood, NJ, U. S.)"},{"key":"10.1016\/j.canlet.2026.218780_bib101","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/cr.2016.132","article-title":"Inhibiting macrophage PI3K\u03b3 to enhance immunotherapy","volume":"26","author":"Zheng","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218780_bib102","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15R\u03b1 fusion complex protects and rescues NK cell-cytotoxic function from TGF-\u03b21-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218780_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2026.100203","article-title":"Nanocarrier-based strategies for advanced cancer drug delivery and therapeutics: design principles, biological interactions, and clinical potential","volume":"14","author":"Jayaraj","year":"2026","journal-title":"Nano Trends"},{"key":"10.1016\/j.canlet.2026.218780_bib104","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S575214","article-title":"Precision pediatric cancer nanomedicine: advancing personalized nano therapies to reduce non-communicable diseases through AI-Driven 3D-Printed drugs","volume":"21","author":"Choudhary","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218780_bib105","article-title":"Recent advances in nanoparticles-based sonodynamic and immune checkpoint blockade synergistic therapy for pancreatic ductal adenocarcinoma","volume":"35","author":"Li","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.canlet.2026.218780_bib106","article-title":"A comprehensive review on the biomass-mediated synthesis of silver nanoparticles: opportunities and challenges","volume":"13","author":"Kumar","year":"2025","journal-title":"J. Environ. Chem. Eng."},{"key":"10.1016\/j.canlet.2026.218780_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123047","article-title":"Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy","volume":"317","author":"Yu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218780_bib108","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.apsb.2025.02.040","article-title":"Nano-drug delivery strategies affecting cancer-associated fibroblasts to reduce tumor metastasis","volume":"15","author":"Zou","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218780_bib120","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","article-title":"Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications","volume":"44","author":"Liu","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib123","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T-cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41419-020-02961-5","article-title":"(+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218780_bib127","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218780_bib128","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2023.06.021","article-title":"Large-scale snake genome analyses provide insights into vertebrate development","volume":"186","author":"Peng","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib131","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41467-021-23626-7","article-title":"4D analysis of malaria parasite invasion offers insights into erythrocyte membrane remodeling and parasitophorous vacuole formation","volume":"12","author":"Geoghegan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218780_bib132","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2021.06.009","article-title":"Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6\/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma","volume":"518","author":"Zhao","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218780_bib133","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/0008-5472.CAN-21-0684","article-title":"The role of psychologic stress in cancer initiation: clinical relevance and potential molecular mechanisms","volume":"81","author":"Falcinelli","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib134","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.ymthe.2021.06.001","article-title":"Bifunctional TGF-\u03b2 trap\/IL-15 protein complex elicits potent NK cell and CD8+ T-cell immunity against solid tumors","volume":"29","author":"Liu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15R\u03b1 fusion complex protects and rescues NK cell-cytotoxic function from TGF-\u03b21-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218780_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119047","article-title":"The tumor ecosystem: rewiring an open, systemically integrated network for therapeutic gain","volume":"195","author":"Chiodelli","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218780_bib138","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1158\/0008-5472.CAN-16-0386","article-title":"Stimulation of natural killer cell-mediated tumor immunity by an IL-15\/TGF\u03b2-Neutralizing fusion protein","volume":"76","author":"Ng","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib139","first-page":"222","volume":"86","author":"Malik","year":"2025"},{"key":"10.1016\/j.canlet.2026.218780_bib140","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002312","article-title":"Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control","volume":"6","author":"Marimuthu","year":"2025","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib141","doi-asserted-by":"crossref","DOI":"10.4253\/wjge.v17.i9.109144","article-title":"Endoscopic submucosal dissection for early gastrointestinal malignancies: current state and future perspectives","volume":"17","author":"Pal","year":"2025","journal-title":"World J. Gastrointest. Endosc."},{"key":"10.1016\/j.canlet.2026.218780_bib142","article-title":"Advances in endoscopic techniques for early detection and treatment of gastrointestinal cancers: a systematic review","volume":"104","author":"Mastoi","year":"2025","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.canlet.2026.218780_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/jfb16100381","article-title":"Bioengineered in situ-forming hydrogels as smart drug delivery systems for postoperative breast cancer immunotherapy: from material innovation to clinical translation","volume":"16","author":"Yan","year":"2025","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.canlet.2026.218780_bib144","article-title":"Chitosan-based materials and strategies in immunotherapy and synergistic immunochemotherapy: a focus on gene-based immunoregulation and CAR-T and adoptive cell transfer","volume":"11","author":"Safarzadeh","year":"2025","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"10.1016\/j.canlet.2026.218780_bib145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1423143","article-title":"The investigation of oncolytic viruses in the field of cancer therapy","volume":"14","author":"Yuan","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib147","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib148","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.7150\/ijbs.96338","article-title":"Bridging chronic inflammation and digestive cancer: the critical role of innate lymphoid cells in tumor microenvironments","volume":"20","author":"Shen","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218780_bib149","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1021\/acsami.4c09065","article-title":"Investigating T-cell immune dynamics and IL-6's duality in a microfluidic lung tumor model","volume":"17","author":"Sardarabadi","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218780_bib150","article-title":"Microfluidic system to analyze the effects of interleukin 6 on lymphatic breast cancer metastasis","volume":"8","author":"Cho","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218780_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218780_bib152","series-title":"Engineering Technologies and Clinical Translation","first-page":"155","article-title":"Chapter six - tumor-on-a-chip devices for cancer immunotherapy","author":"Mu","year":"2022"},{"key":"10.1016\/j.canlet.2026.218780_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00985-1","article-title":"Spatiotemporal dynamics of a glioma immune interaction model","volume":"11","author":"Khajanchi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218780_bib154","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib155","series-title":"Current Cancer Therapy Reviews","article-title":"Advancing NK cell therapies: expansion and activation for next-generation immunotherapy","author":"Kumar","year":"2025"},{"key":"10.1016\/j.canlet.2026.218780_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226518","article-title":"19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and antitumor effect in vivo","volume":"14","author":"Silvestre","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib157","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00262-019-02372-2","article-title":"3rd, an IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck","volume":"68","author":"Pinette","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218780_bib158","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL-15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib159","article-title":"In situ forming hydrogels for colorectal cancer therapy","volume":"35","author":"Yao","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.canlet.2026.218780_bib162","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib163","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001498","article-title":"Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T-cells in deficient mismatch repair colorectal cancer","volume":"9","author":"Sui","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2010.74","article-title":"The journal of cancer gene and cellular therapies","volume":"18","author":"Sobol","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1002721","article-title":"IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity","volume":"4","author":"Bahri","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2026.218780_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152035","article-title":"Late-stage MC38 tumors recapitulate features of human colorectal cancer - implications for appropriate timepoint selection in preclinical studies","volume":"14","author":"Shields","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib167","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.3390\/cancers12102880","article-title":"Non-invasive early molecular detection of gastric cancers","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib168","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/cancers11010040","article-title":"IL-15 and a two-step maturation process improve bone marrow-derived dendritic cell cancer vaccine","volume":"11","author":"Mookerjee","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines9010064","article-title":"Tumor-infiltrating lymphoid cells in colorectal cancer patients with varying disease stages and microsatellite instability-High\/Stable tumors","volume":"9","author":"Toor","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.canlet.2026.218780_bib170","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.3390\/cancers13235910","article-title":"Colorectal cancer stem cells: an overview of evolving methods and concepts","volume":"13","author":"De Angelis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib171","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13046-023-02833-8","article-title":"Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation","volume":"42","author":"Xie","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib172","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3390\/cancers12123850","article-title":"Mechanisms of immunosuppression in colorectal cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib173","article-title":"T-cells in colorectal cancer: unravelling the function of different T-cell subsets in the tumor microenvironment","volume":"24","author":"Zheng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218780_bib174","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cells12081139","article-title":"TGF\u03b2 and the tumor microenvironment in colorectal cancer","volume":"12","author":"Waldner","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218780_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112156","article-title":"IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: from bench to bedside","volume":"133","author":"Vahidi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218780_bib176","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/gels11110889","article-title":"Hydrogels in the immune context: in vivo applications for modulating immune responses in cancer therapy","volume":"11","author":"Lanis","year":"2025","journal-title":"Gels"},{"key":"10.1016\/j.canlet.2026.218780_bib177","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12967-024-04982-6","article-title":"Combined therapy of CAR-IL-15\/IL-15R\u03b1-T-cells and GLIPR1 knockdown in cancer cells enhanced antitumor effect against gastric cancer","volume":"22","author":"Ye","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib195","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218780_bib196","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218780_bib197","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib198","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12672-022-00479-0","article-title":"PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis","volume":"13","author":"Lima","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib200","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181374","article-title":"68Ga-FAPI PET imaging monitors response to combined TGF-\u03b2R inhibition and immunotherapy in metastatic colorectal cancer","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218780_bib201","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging\u2014An updated review","volume":"13","author":"Chandekar","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.canlet.2026.218780_bib202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00066-023-02117-2","article-title":"Dual-tracer PET\/CT protocol with [(18)F]FDG and [(68)Ga]Ga-FAPI-46 outperforms single-tracer PET\/CT with [(18)F]FDG in different cancer types, resulting in larger functional and gross tumor volume","volume":"200","author":"Wegen","year":"2024","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.canlet.2026.218780_bib203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-025-01754-7","article-title":"Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities","volume":"18","author":"Deng","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib204","doi-asserted-by":"crossref","DOI":"10.1093\/jimmun\/vkaf314","article-title":"IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T-cell\u2013dependent and NK cell\u2013independent manner in a murine model of pancreatic ductal adenocarcinoma","author":"Burrack","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020392","article-title":"Predicting microenvironment in CXCR4- and FAP-positive solid Tumors-A pan-cancer machine learning workflow for Theranostic target structures","volume":"15","author":"Marquardt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.immuni.2009.04.020","article-title":"Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T-cells","volume":"31","author":"Sanjabi","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218780_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17122001","article-title":"Blood-based biomarkers as predictive and prognostic factors in immunotherapy-treated patients with solid tumors-currents and perspectives","volume":"17","author":"Kaczmarek","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218780_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2026.100176","article-title":"Alcohol-induced extracellular vesicle signatures: exploring liquid biopsy biomarkers for early cancer detection and prognosis","volume":"16","author":"Choudhary","year":"2026","journal-title":"Adv. Cancer Biol. Metastasis"},{"key":"10.1016\/j.canlet.2026.218780_bib180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib181","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10238-025-01676-1","article-title":"Cytokine profiles as predictive biomarkers for treatment outcomes in advanced gastric cancer patients undergoing PD-1 blockade immunochemotherapy: a meta-analysis","volume":"25","author":"Yang","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100881","article-title":"Epstein-barr virus\u2013associated gastric cancer: a histopathologic study with comprehensive molecular profiling","volume":"38","author":"Angerilli","year":"2025","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2026.218780_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102737","article-title":"The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: a systematic review","volume":"127","author":"Bos","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218780_bib184","doi-asserted-by":"crossref","first-page":"82","DOI":"10.62347\/TUZI7617","article-title":"Multivalent FAPI-based radiopharmaceuticals in PET\/CT: from cancer diagnostics to theranostics","volume":"15","author":"Zhao","year":"2025","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.canlet.2026.218780_bib185","article-title":"Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib186","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2967\/jnumed.124.268289","article-title":"Approaches to imaging immune activation using PET","volume":"66","author":"Parihar","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib187","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1016\/j.apsb.2025.07.009","article-title":"Fibroblast activation protein targeting radiopharmaceuticals: from drug design to clinical translation","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218780_bib188","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220749","article-title":"Fapi PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.canlet.2026.218780_bib189","article-title":"Clinical utility of FAPI PET\/CT in diagnosis, staging, and response assessment of colorectal cancer","author":"Xie","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib190","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/jcm12020577","article-title":"FAPI PET\/CT in diagnostic and treatment management of colorectal cancer: Review of current research status","volume":"12","author":"Cheng","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib191","first-page":"7","article-title":"Applications of multiplex immunohistochemistry in evaluating spatiotemporal heterogeneity of T-cells","volume":"5","author":"Machuca-Ostos","year":"2025","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2026.218780_bib192","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28944-3","article-title":"Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma","volume":"8","author":"Halse","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218780_bib193","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1016\/j.cell.2023.11.006","article-title":"Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors","volume":"186","author":"Heiser","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib194","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/cancers15041193","article-title":"The superiority of Fibroblast activation Protein Inhibitor (FAPI) PET\/CT versus FDG PET\/CT in the diagnosis of various malignancies","volume":"15","author":"Dong","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib207","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib208","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218780_bib209","article-title":"ALT-803 in the treatment of non-muscle-invasive bladder cancer: preclinical and clinical evidence and translational potential","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/biomedicines13040930","article-title":"CD8+ T-cell subsets as biomarkers for predicting checkpoint therapy outcomes in cancer immunotherapy","volume":"13","author":"Casalegno Gardu\u00f1o","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218780_bib211","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, A novel recombinant IL-15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib212","article-title":"To Ki or not to ki: Re-evaluating the use and potentials of Ki-67 for T-cell analysis","volume":"12","author":"Di Rosa","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218780_bib213","article-title":"Integrative multi-omics deciphers the spatial characteristics of host-gut microbiota interactions in Crohn's disease","volume":"4","author":"Gao","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218780_bib214","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13046-025-03509-1","article-title":"Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies","volume":"44","author":"Zhao","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218780_bib215","article-title":"Natural killer cell-mediated antitumor immunity: molecular mechanisms and clinical applications","volume":"6","author":"Luo","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218780_bib216","first-page":"924","article-title":"Biomaterials nanoplatform-based tumor vaccines for immunotherapy","volume":"51","author":"Li","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.canlet.2026.218780_bib217","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2051-1426-1-5","article-title":"Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation","volume":"1","author":"Vatsan","year":"2013","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2025.100222","article-title":"New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation","volume":"8","author":"Bettinsoli","year":"2025","journal-title":"Curr. Res. Toxicol."},{"key":"10.1016\/j.canlet.2026.218780_bib219","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral injection of immunotherapeutics: state of the art and future directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.canlet.2026.218780_bib220","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ccell.2021.04.002","article-title":"Artificial intelligence for clinical oncology","volume":"39","author":"Kann","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218780_bib233","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral immunotherapy-update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218780_bib221","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/vaccines11111717","article-title":"Immunotherapeutic agents for intratumoral immunotherapy","volume":"11","author":"Shyr","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.canlet.2026.218780_bib222","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1940-6207.CAPR-15-0234","article-title":"The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them","volume":"8","author":"Finn","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib223","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1606599","article-title":"Reporting of immune-related adverse events in US Food and drug administration approvals of immune checkpoint inhibitors","volume":"15","author":"Tapiavala","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.jallcom.2025.185228","article-title":"Non-orthopaedic applications of mesoporous bioactive glasses (MBGs): a comprehensive review of design principles, preclinical evidence, and translational pathways","volume":"1048","author":"Shoaib","year":"2025","journal-title":"J. Alloys Compd."},{"key":"10.1016\/j.canlet.2026.218780_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108612","article-title":"Advanced therapy medicinal products development - from guidelines to medicines in the market","volume":"83","author":"Frederico","year":"2025","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.canlet.2026.218780_bib226","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2147\/CCID.S549199","article-title":"Langerin(+) dendritic cells in cutaneous fibrosis: the TGF-\u03b21 signaling axis","volume":"18","author":"Lv","year":"2025","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2026.218780_bib227","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.gie.2012.03.177","article-title":"Development of innovative techniques for the endoscopic implantation and securing of a novel, wireless, miniature gastrostimulator (with videos)","volume":"76","author":"Deb","year":"2012","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.canlet.2026.218780_bib228","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-319-18618-4_8","article-title":"Regulatory frameworks for gene and cell therapies in Japan","volume":"871","author":"Maeda","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2026.218780_bib229","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-031-34567-8_6","article-title":"Canadian regulatory framework and regulatory requirements for cell and gene therapy products","volume":"1430","author":"Wang","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2026.218780_bib230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/picr.PICR_208_19","article-title":"New drugs and clinical trials rules 2019: changes in responsibilities of the ethics committee","volume":"11","author":"Singh","year":"2020","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.canlet.2026.218780_bib231","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clinthera.2021.02.006","article-title":"Advanced therapies and regulatory framework in different areas of the globe: past, present, and future","volume":"43","author":"Pimenta","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.canlet.2026.218780_bib232","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1535370217740861","article-title":"The FDA oncology center of excellence and precision medicine","volume":"243","author":"Goldberg","year":"2018","journal-title":"Exp. Biol. Med. (Maywood, NJ, U. S.)"},{"key":"10.1016\/j.canlet.2026.218780_bib234","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41571-024-00892-0","article-title":"NIR-II light in clinical oncology: opportunities and challenges","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218780_bib235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib236","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst."},{"key":"10.1016\/j.canlet.2026.218780_bib237","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218780_bib238","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S568254","article-title":"Nanotechnology-driven cancer therapies for precision oncology: advances and clinical outlook","volume":"21","author":"Gupta","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218780_bib239","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12943-025-02476-7","article-title":"Nanoparticle-based strategy in CAR-T-cell immunotherapy: challenges, implications, and perspectives","volume":"24","author":"Shang","year":"2025","journal-title":"Mol. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:33:10Z","timestamp":1789108390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":233,"alternative-id":["S0304383526005446"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218780","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-15 superagonists for reprogramming the immunosuppressive microenvironment in gastrointestinal adenocarcinomas","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218780"}}